Calponin 3 suppresses proliferation, migration and invasion of non‑small cell lung cancer cells

Yang,Chenglin; Zhu,Shiping; Feng,Weifeng; Chen,Xuexin

doi:10.3892/ol.2021.12895

Calponin 3 suppresses proliferation, migration and invasion of non‑small cell lung cancer cells

Authors:
- Chenglin Yang
- Shiping Zhu
- Weifeng Feng
- Xuexin Chen
View Affiliations

Affiliations: Traditional Chinese Medicine Department, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510632, P.R. China, Department of Respiratory and Critical Care Medicine, The General Hospital of Yima Coal Industry Group Co. Ltd., Yima, Henan 472300, P.R. China
Published online on: July 1, 2021 https://doi.org/10.3892/ol.2021.12895
Article Number: 634
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Calponin 3 (CNN3) is known to serve a role in certain types of cancer, such as gastric cancer and colorectal cancer. The present study investigated the clinical significance of CNN3 in non‑small cell lung cancer (NSCLC) by evaluating its expression profile and relationship with disease prognosis using the Gene Expression Omnibus repository, Gene Expression Profiling Interactive Analysis 2 (GEPIA2) and Kaplan‑Meier plotter analysis. CNN3 mRNA expression was measured using reverse transcription‑quantitative PCR, while the protein expression level was measured using western blot analysis. Cell proliferation, cell cycle and apoptosis, and migration and invasion were analyzed using MTS assay, flow cytometry and Transwell assays, respectively. These results revealed that CNN3 mRNA expression was downregulated in NSCLC tissues compared with that in normal tissues. Additionally, CNN3 expression had a high diagnostic value based on the GSE2514 dataset and the data from The Cancer Genome Atlas and the Genotype Tissue Expression database, whereas it had a low diagnostic value based on the GSE10072 dataset. Furthermore, CNN3 expression was associated with survival in patients with lung adenocarcinoma (LUAD), whereas it was not associated with survival in patients with lung squamous cell carcinoma (LUSC) according to the Kaplan‑Meier plotter results. According to the data from GEPIA2, and the GSE72094, GSE41271 and GSE31210 datasets, CNN3 expression was not associated with the prognosis of patients with LUAD and LUSC. The mRNA and protein expression levels of CNN3 were lower in two NSCLC cell lines (A549 and SK‑MES‑1) than in a human bronchial epithelial cell line (BEAS‑2B). CNN3 overexpression suppressed cell proliferation, migration and invasion, induced G1‑phase arrest, promoted apoptosis and suppressed PI3K/AKT signaling pathway activation in the NSCLC cell lines, whereas CNN3 overexpression had no effect on cell morphology. In conclusion, CNN3 suppressed the proliferation and metastasis of NSCLC cells by downregulating the PI3K/AKT signaling pathway, making it a potential therapeutic target in this disease.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387. 2018. View Article : Google Scholar : PubMed/NCBI
4	Cao M and Chen W: Epidemiology of lung cancer in China. Thorac Cancer. 10:3–7. 2019. View Article : Google Scholar : PubMed/NCBI
5	Richard PJ and Rengan R: Oligometastatic non-small-cell lung cancer: Current treatment strategies. Lung Cancer (Auckl). 7:129–140. 2016.PubMed/NCBI
6	Fischer C, Leithner K, Wohlkoenig C, Quehenberger F, Bertsch A, Olschewski A, Olschewski H and Hrzenjak A: Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization. Mol Cancer. 14:42015. View Article : Google Scholar : PubMed/NCBI
7	Lakshmi SP, Reddy AT, Banno A and Reddy RC: PPAR agonists for the prevention and treatment of lung cancer. Ppar Res. 2017:82527962017. View Article : Google Scholar : PubMed/NCBI
8	Mohamad N, Jayalakshmi P, Rhodes A, Liam CK, Tan JL and Yousoof S: Anaplastic lymphoma kinase (ALK) mutations in patients with adenocarcinoma of the lung. Br J Biomed Sci. 74:176–180. 2017. View Article : Google Scholar : PubMed/NCBI
9	Virmani AK and Gazdar AF: Tumor suppressor genes in lung cancer. Methods Mol Biol. 222:97–115. 2003.PubMed/NCBI
10	Ghafouri-Fard S, Shoorei H, Branicki W and Taheri M: Non-coding RNA profile in lung cancer. Exp Mol Pathol. 114:1044112020. View Article : Google Scholar : PubMed/NCBI
11	Topchu I, Karnaukhov N, Mazitova A, Yugai V, Voloshin M, Tikhomirova M, Kit O, Frantsiyants E, Kharin L, Airapetova T, et al: Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC). J Thorac Dis. 13:1370–1379. 2021. View Article : Google Scholar : PubMed/NCBI
12	Chen J, Shao J, Shen A, Zhu X, Zhang X, Sun H, Wei S and Ling Y: Enhanced expression of FGF19 predicts poor prognosis in patients with non-small cell lung cancer. J Thorac Dis. 13:1769–1784. 2021. View Article : Google Scholar : PubMed/NCBI
13	Wang H, Jiang X, Cheng Y, Ren H, Hu Y, Zhang Y, Su H, Zou Z, Wang Q, Liu Z, et al: MZT2A promotes NSCLC viability and invasion by increasing Akt phosphorylation via the MOZART2 domain. Cancer Sci. 112:2210–2222. 2021. View Article : Google Scholar : PubMed/NCBI
14	Takahashi K and Nadal-Ginard B: Molecular cloning and sequence analysis of smooth muscle calponin. J Biol Chem. 266:13284–13288. 1991. View Article : Google Scholar : PubMed/NCBI
15	Rami G, Caillard O, Medina I, Pellegrino C, Fattoum A, Ben-Ari Y and Ferhat L: Change in the shape and density of dendritic spines caused by overexpression of acidic calponin in cultured hippocampal neurons. Hippocampus. 16:183–197. 2006. View Article : Google Scholar : PubMed/NCBI
16	Daimon E, Shibukawa Y and Wada Y: Calponin 3 regulates stress fiber formation in dermal fibroblasts during wound healing. Arch Dermatol Res. 305:571–584. 2013. View Article : Google Scholar : PubMed/NCBI
17	Shibukawa Y, Yamazaki N, Daimon E and Wada Y: Rock-dependent calponin 3 phosphorylation regulates myoblast fusion. Exp Cell Res. 319:633–648. 2013. View Article : Google Scholar : PubMed/NCBI
18	Xia L, Yue Y, Li M, Zhang YN, Zhao L, Lu W, Wang X and Xie X: CNN3 acts as a potential oncogene in cervical cancer by affecting RPLP1 mRNA expression. Sci Rep. 10:24272020. View Article : Google Scholar : PubMed/NCBI
19	Hong KS, Kim H, Kim SH, Kim M and Yoo J: Calponin 3 regulates cell invasion and doxorubicin resistance in gastric cancer. Gastroenterol Res Pract. 2019:30249702019. View Article : Google Scholar : PubMed/NCBI
20	Nakarai C, Osawa K, Akiyama M, Matsubara N, Ikeuchi H, Yamano T, Hirota S, Tomita N, Usami M and Kido Y: Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer. Clin Exp Med. 15:333–341. 2015. View Article : Google Scholar : PubMed/NCBI
21	Dai F, Luo F, Zhou R, Zhou Q, Xu J, Zhang Z, Xiao J and Song L: Calponin 3 is associated with poor prognosis and regulates proliferation and metastasis in osteosarcoma. Aging (Albany NY). 12:14037–14049. 2020. View Article : Google Scholar : PubMed/NCBI
22	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
23	Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA Jr, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, et al: Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol. 167:1763–1775. 2005. View Article : Google Scholar : PubMed/NCBI
24	Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et al: Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One. 3:e16512008. View Article : Google Scholar : PubMed/NCBI
25	Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, et al: Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 35:3209–3216. 2016. View Article : Google Scholar : PubMed/NCBI
26	Sato M, Larsen JE, Lee W, Sun H, Shames DS, Dalvi MP, Ramirez RD, Tang H, DiMaio JM, Gao B, et al: Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res. 11:638–650. 2013. View Article : Google Scholar : PubMed/NCBI
27	Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S, et al: Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 72:100–111. 2012. View Article : Google Scholar : PubMed/NCBI
28	Tang Z, Kang B, Li C, Chen T and Zhang Z: GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47:W556–W560. 2019. View Article : Google Scholar : PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
30	Nair VA, Al-Khayyal NA, Sivaperumal S and Abdel-Rahman WM: Calponin 3 promotes invasion and drug resistance of colon cancer cells. World J Gastrointest Oncol. 11:971–982. 2019. View Article : Google Scholar : PubMed/NCBI
31	Jiang X, Qin Y, Kun L and Zhou Y: The significant role of the microfilament system in tumors. Front Oncol. 11:6203902021. View Article : Google Scholar : PubMed/NCBI
32	Ediriweera MK, Tennekoon KH and Samarakoon SR: Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 59:147–160. 2019. View Article : Google Scholar : PubMed/NCBI
33	Zhang X, He X, Liu Y, Zhang H, Chen H, Guo S and Liang Y: MiR-101-3p inhibits the growth and metastasis of non-small cell lung cancer through blocking PI3K/AKT signal pathway by targeting MALAT-1. Biomed Pharmacother. 93:1065–1073. 2017. View Article : Google Scholar : PubMed/NCBI
34	Chen H, Zhou L, Wu X, Li R, Wen J, Sha J and Wen X: The PI3K/AKT pathway in the pathogenesis of prostate cancer. Front Biosci (Landmark Ed). 21:1084–1091. 2016. View Article : Google Scholar : PubMed/NCBI
35	Martini M, De Santis MC, Braccini L, Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
36	Yang J, Cron P, Thompson V, Good VM, Hess D, Hemmings BA and Barford D: Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell. 9:1227–1240. 2002. View Article : Google Scholar : PubMed/NCBI
37	Calera MR, Martinez C, Liu H, Jack AK, Birnbaum MJ and Pilch PF: Insulin increases the association of Akt-2 with Glut4-containing vesicles. J Biol Chem. 273:7201–7204. 1998. View Article : Google Scholar : PubMed/NCBI
38	Gao X, Wang N, Wu S, Cui H, An X and Yang Y: Long noncoding RNA FER1L4 inhibits cell proliferation and metastasis through regulation of the PI3K/AKT signaling pathway in lung cancer cells. Mol Med Rep. 20:182–190. 2019.PubMed/NCBI